Arteriosclerosis Obliterans Market Summary

·        Arteriosclerosis obliterans is also known as Peripheral Artery Disease (PAD) is a chronic occlusive disease where plaque buildup hardens and narrows the arteries, restricting blood flow to the lower extremities.

·        PAD is a narrowing or blockage of peripheral arteries that reduces blood flow from the heart and brain to other parts of the body, most commonly affecting the lower extremities, including the legs and feet.

·        Despite its high prevalence, PAD remains substantially underdiagnosed, with studies suggesting that approximately 40–60% of patients are not identified in primary care settings, largely due to its asymptomatic or atypical clinical presentation.

·        Lower extremity arteriosclerosis obliterans (LEASO) represents the most common clinical manifestation of PAD, characterized by progressive atherosclerotic narrowing of lower limb arteries and serving as the primary driver of morbidity, including claudication and limb-threatening ischemia.

·        The treatment for arteriosclerosis obliterans remains focused on symptom management, cardiovascular risk reduction, and prevention of disease progression.

·        The current treatment of arteriosclerosis obliterans focuses on symptom relief, cardiovascular risk reduction, and prevention of disease progression through lifestyle modification, exercise, antiplatelet and lipid-lowering therapy. Severe or refractory cases may require endovascular revascularization or surgical bypass to improve limb perfusion.

·        The pipline is not so robust and consists of therapies like orforglipron (LY3502970)    (Eli Lily), selexipag (NS-304)        (Nippon Shinyaku), CLBS12         (Lisata Therapeutics), and VT-141 (Venturis Therapeutics) among others.

·        Selexipag’s existing commercial experience in pulmonary arterial hypertension provides clinical validation, but penetration into arteriosclerosis obliterans/PAD remains limited due to lack of definitive PAD outcome trials.

·        Patients with critical limb ischemia/chronic limb-threatening ischemia (CLTI) represent the highest-risk population, with significant morbidity, amputation risk, and healthcare costs, creating demand for therapies improving limb outcomes.

Arteriosclerosis Obliterans Market Size and Forecast in the 7MM

• 2025 Arteriosclerosis Obliterans Market Size: XX million
• 2036 Projected Arteriosclerosis Obliterans Market Size: XX million
• Arteriosclerosis Obliterans Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Arteriosclerosis Obliterans – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the arteriosclerosis obliterans, historical and forecasted epidemiology, as well as the Arteriosclerosis obliterans market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Arteriosclerosis obliterans market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Arteriosclerosis obliterans patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in arteriosclerosis obliterans and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Arteriosclerosis Obliterans Market

Rising Prevalence of Peripheral Artery Disease (PAD) and Aging Population

Increasing life expectancy and the growing burden of diabetes, hypertension, dyslipidemia, and smoking are driving the incidence of arteriosclerosis obliterans, expanding the eligible patient population.

Increasing Adoption of Minimally Invasive Revascularization Procedures

The growing use of endovascular interventions such as angioplasty, stenting, and atherectomy has increased demand for adjunctive medical therapies to prevent restenosis and improve long-term outcomes.

Expanding Use of Evidence-Based Cardiovascular Therapies

Greater adoption of antiplatelet agents, anticoagulants, statins, PCSK9 inhibitors, and other lipid-lowering therapies is improving cardiovascular risk management in ASO patients and supports demand across the treatment landscape.

Arteriosclerosis Obliterans Understanding and Treatment Algorithm

Arteriosclerosis Obliterans Overview and Diagnosis

Arteriosclerosis obliterans is a chronic, progressive atherosclerotic vascular disorder characterized by the narrowing or occlusion of peripheral arteries, most commonly in the lower limbs. It represents the primary clinical manifestation of PAD and leads to reduced blood flow, resulting in symptoms ranging from asymptomatic disease to intermittent claudication and, in advanced stages, chronic limb-threatening ischemia (CLTI). Arteriosclerosis obliterans is strongly associated with systemic atherosclerosis and significantly increases the risk of cardiovascular events such as myocardial infarction and stroke, with major risk factors including smoking, diabetes, hypertension, dyslipidemia, and advanced age.

Diagnosis of arteriosclerosis obliterans is based on clinical evaluation supported by non-invasive vascular testing and imaging modalities. Key clinical features include exertional leg pain (intermittent claudication), rest pain, reduced peripheral pulses, and in severe cases, non-healing ulcers or gangrene. The ankle-brachial index (ABI) is the first-line diagnostic tool, with values ≤0.90 indicating PAD/arteriosclerosis obliterans. Imaging techniques such as duplex ultrasound, CT angiography, MR angiography, and digital subtraction angiography are used to confirm disease severity and guide treatment decisions, while functional assessments like treadmill testing help evaluate disease impact on mobility and quality of life.

Further details are provided in the report.

Current Arteriosclerosis Obliterans Treatment Landscape

Arteriosclerosis obliterans treatment focuses on relieving ischemic symptoms, improving limb perfusion, and reducing cardiovascular and limb-related events through lifestyle modification, pharmacotherapy, and revascularization. Standard treatment includes antiplatelet agents, statins, and symptom-relieving drugs such as cilostazol, beraprost, limaprost, and sarpogrelate, while advanced cases may require endovascular intervention or surgical bypass.

Further details related to country-based variations are provided in the report.

Arteriosclerosis Obliterans Unmet Needs

The section “unmet needs of arteriosclerosis obliterans” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited disease-modifying therapies
2. High risk of cardiovascular and limb events
3. Delay in diagnosis as many patients are diagnosed at advanced stages
4. Poor long-term adherence, and others…..

Note: Comprehensive unmet needs insights in Arteriosclerosis Obliterans and their strategic implications are provided in the full report.

Arteriosclerosis Obliterans Epidemiology

Key Findings from Arteriosclerosis Obliterans Epidemiological Analysis and Forecast

·        Arteriosclerosis obliterans is responsible for 95% of chronic occlusive arterial disease, most commonly affects patients over age 50, and affects men more than women 

·        The disease shows a strong age-related pattern, with the highest prevalence observed in the 60–74 years age group, reflecting cumulative exposure to cardiovascular risk factors such as smoking, diabetes, and hypertension.

·        Males exhibiting higher PAD-related mortality before the age of 75 years, while females show comparatively higher mortality rates after 75 years, likely influenced by later disease recognition and greater longevity.

Arteriosclerosis Obliterans Drug Analysis & Competitive Landscape

The arteriosclerosis obliterans drug chapter provides a detailed, market-focused review of the emerging pipeline across Phase II/I clinical trials and preclinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the arteriosclerosis obliterans treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the arteriosclerosis obliterans therapeutics market.

Approved Therapies for Arteriosclerosis Obliterans

First-line care includes lifestyle interventions such as supervised exercise therapy, smoking cessation, weight management, and control of cardiovascular risk factors. Pharmacological management is primarily based on off-label use of agents including antiplatelet therapies (aspirin, clopidogrel) to reduce thrombotic risk, statins for lipid lowering and vascular protection, and cilostazol to improve intermittent claudication symptoms by enhancing walking distance.

In selected patients, rivaroxaban combined with aspirin may be used based on evidence from PAD populations. Other supportive treatments, including analgesics for ischemic pain and management of diabetes and hypertension, are used to reduce complications. Despite these approaches, significant unmet need remains for therapies targeting disease progression and restoring peripheral blood flow in ASO patients.

Note: Detailed marketed therapies assessment will be provided in the final report.

Arteriosclerosis Obliterans Pipeline Analysis

Orforglipron (LY3502970): Eli Lily

Orforglipron is an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist for metabolic diseases, including obesity and type 2 diabetes, with potential cardiovascular benefits relevant to arteriosclerosis obliterans. It improves glucose control, promotes weight loss, and reduces cardiometabolic risk factors through enhanced insulin secretion, reduced glucagon release, and delayed gastric emptying. It is being studied for the treatment of PAD.

Selexipag (NS-304): Nippon Shinyaku

Selexipag is an oral, selective prostacyclin (IP) receptor agonist being developed by Nippon Shinyaku for the treatment of arteriosclerosis obliterans with intermittent claudication. By activating the IP receptor, selexipag promotes vasodilation, inhibits platelet aggregation, and suppresses vascular smooth muscle cell proliferation, thereby improving peripheral blood flow.

The drug is currently in Phase III clinical development in Japan, where it is being evaluated for its ability to improve walking performance and exercise capacity in patients with arteriosclerosis obliterans.

Note: Detailed emerging therapies assessment will be provided in the final report.

Arteriosclerosis Obliterans Key Players, Market Leaders and Emerging Companies

• Eli Lily
• Nippon Shinyaku
• Lisata Therapeutics
• Venturis, and others

Arteriosclerosis Obliterans Drug Updates

• Eli Lily in its 2026 Q2 earnings presentation expectes Arteriosclerosis Obliterans for PAD in 2027 or beyond.

Arteriosclerosis Obliterans Market Outlook

The treatment landscape for arteriosclerosis obliterans remains largely focused on symptom management, cardiovascular risk reduction, and revascularization, with limited disease-modifying pharmacological options available. Pharmacological treatment primarily includes cilostazol, along with regionally used agents such as beraprost, limaprost, and sarpogrelate, particularly for the management of intermittent claudication and associated symptoms.

Among emerging therapies, selexipag represents one of the most advanced pharmacological candidates specifically targeting arteriosclerosis obliterans-associated intermittent claudication. If successful, selexipag could provide a differentiated oral therapy by improving vascular tone and blood flow beyond currently available symptomatic treatments. Regenerative medicine approaches such as CLBS12, aim to address the unmet need in patients by promoting angiogenesis and tissue repair. Similarly, VT-141 is an emerging approach focused on restoring perfusion and improving ischemic tissue recovery, although clinical development remains at an early stage.

Overall, the arteriosclerosis obliterans market is expected to demonstrate gradual growth across the 7MM, driven by the rising prevalence of diabetes, obesity, aging populations, improved PAD diagnosis, and increasing demand for therapies that reduce amputation risk and improve quality of life. However, market expansion will depend on successful clinical validation and adoption of emerging disease-modifying and regenerative therapies, as the current landscape remains dominated by low-cost generic symptomatic treatments.

sFurther details will be provided in the report….

Drug Class/Insights into Leading Emerging Therapies in Arteriosclerosis Obliterans (2022–2036 Forecast)

The arteriosclerosis obliterans market (2022–2036 forecast) is primarily driven by therapies aimed at improving peripheral blood flow, reducing ischemic symptoms, promoting vascular regeneration, and addressing underlying cardiometabolic risk factors.

• GLP-1 Receptor Agonists: Orforglipron although not specifically developed for arteriosclerosis obliterans, GLP-1 agonists may provide indirect benefits through weight reduction, improved glycemic control, reduced inflammation, and cardiovascular risk modification, addressing key risk factors associated with arteriosclerosis obliterans progression.
• IP Receptor Agonists: Selexipag represents the prostacyclin receptor agonist class. By selectively activating the IP receptor, selexipag promotes vasodilation, inhibits platelet aggregation, and reduces vascular smooth muscle proliferation.

Overall, innovation in the arteriosclerosis obliterans market is shifting from conventional symptomatic therapies toward vascular regenerative therapies, prostacyclin pathway modulators, and cardiometabolic-targeted approaches. While current treatment remains dominated by generic vasodilators and cardiovascular risk-management drugs. These advancements are expected to gradually expand the arteriosclerosis obliterans therapeutic landscape through 2036.

Arteriosclerosis Obliterans Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the arteriosclerosis obliterans drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

During the forecast period, the arteriosclerosis obliterans market is expected to remain dominated by established symptomatic therapies. However, emerging therapies may expand treatment options by addressing unmet needs in peripheral perfusion and limb preservation. Selexipag is expected to be the leading pharmacological entrant, with potential adoption driven by its novel prostacyclin IP receptor agonist mechanism and ability to improve walking capacity and blood flow in arteriosclerosis obliterans patients with intermittent claudication. CLBS12 may gain uptake among CLTI patients unsuitable for revascularization, supported by its regenerative angiogenic potential, while VT-141 could establish a niche role if clinical data demonstrate improvements in limb perfusion and tissue repair.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved Therapies in Arteriosclerosis Obliterans

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report….

Arteriosclerosis Obliterans Therapies Price Scenario & Trends

Pricing and analogue assessment of arteriosclerosis obliterans therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Arteriosclerosis Obliterans

To keep up with arteriosclerosis obliterans market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the arteriosclerosis obliterans emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in arteriosclerosis obliterans, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights at the country level. Centers such as Cancer Institute, Boston, Royal Arteriosclerosis Obliterans Society, and Fred Hutchinson Cancer Research Center, etc. were contacted. Their opinion helps understand and validate current and emerging arteriosclerosis obliterans therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in arteriosclerosis obliterans.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of arteriosclerosis obliterans, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical arteriosclerosis obliteransessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of arteriosclerosis obliterans, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the arteriosclerosis obliterans market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM arteriosclerosis obliterans market.

Report Insights

• Arteriosclerosis Obliterans Patient Population Forecast
• Arteriosclerosis Obliterans Therapeutics Market Size
• Arteriosclerosis Obliterans Pipeline Analysis
• Arteriosclerosis Obliterans Market Size and Trends
• Arteriosclerosis Obliterans Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Arteriosclerosis Obliterans Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Arteriosclerosis Obliterans Treatment Addressable Market (TAM)
• Arteriosclerosis Obliterans Competitve Landscape
• Arteriosclerosis Obliterans) Major Companies Insights
• Arteriosclerosis Obliterans Price Trends and Analogue Assessment
• Arteriosclerosis Obliterans Therapies Drug Adoption/Uptake
• Arteriosclerosis Obliterans Therapies Peak Patient Share Analysis

Report Assessment

• Arteriosclerosis Obliterans Current Treatment Practices
• Arteriosclerosis Obliterans Unmet Needs
• Arteriosclerosis Obliterans Clinical Development Analysis
• Arteriosclerosis Obliterans Emerging Drugs Product Profiles
• Arteriosclerosis Obliterans Market attractiveness
• Arteriosclerosis Obliterans Qualitative Analysis (SWOT and conjoint analysis)

FAQs

Market Insights

• What was the arteriosclerosis obliterans market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of arteriosclerosis obliterans?
• What are the disease risks, burdens, and unmet needs of arteriosclerosis obliterans? What will be the growth opportunities across the 7MM concerning the patient population with arteriosclerosis obliterans?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of arteriosclerosis obliterans? What are the current guidelines for treating arteriosclerosis obliterans in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the arteriosclerosis obliterans market.
• Bottom‑up forecasting builds from the affected population to product forecasts, delivering a robust, data‑driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)‑enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data‑driven decisions.